echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cancer Sci: Safety and Efficacy of T-VEC in Japanese Patients with Advanced Melanoma - Phase I Study

    Cancer Sci: Safety and Efficacy of T-VEC in Japanese Patients with Advanced Melanoma - Phase I Study

    • Last Update: 2022-10-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Melanoma is an aggressive skin cancer with an increasing incidence worldwide


    Eligible adult patients with histologically confirmed stage IIIB-IVM1c cutaneous melanoma, who may have received prior systemic anticancer therapy, must have ≥1 injectable lesion, and serum lactate dehydrogenase ≤1.


    RESULTS: Of the 18 enrolled patients (72.


    Taken together, DRR is consistent with that observed in phase III trials of T-VEC in non-Asian patients


     

    Original source:

    Naoya Yamazaki, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.